Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 Sales Top Estimates
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations, with sales up 15.7% year on year to $2.91 billion. The company expects the full year’s revenue to be around $11.
Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Vertex ...
Vertex Pharmaceuticals Incorporated VRTX will report fourth-quarter and full-year 2024 earnings result on Feb. 10, after market close. The Zacks Consensus Estimate for sales and earnings for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback